By Lawrence Sellin | December 3, 2021
A previous article at The American Report identified two “smoking guns” supporting the conclusion that COVID-19 was created in a laboratory.
First, a de facto scientific recipe for the laboratory creation of COVID-19 was described in the 2018 research grant application to the U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) submitted by scientists who directly collaborated with the “bat woman” Zheng-Li Shi of the Wuhan Institute of Virology.
The research proposal explicitly states that bat coronaviruses, collected in southern China by the Wuhan Institute of Virology, would be isolated and genetically sequenced, particularly the spike proteins, which are the binding elements initiating infection.
It was further proposed that spike proteins demonstrating “high risk” for human infection would be artificially combined with other bat coronavirus “backbones,” creating entirely new and potentially dangerous coronaviruses.
The second smoking gun in the DARPA grant application was the artificial insertion of furin polybasic cleavage sites, short sequences of amino acids e.g. proline-arginine-arginine-alanine or PRRA, long-known to increase infectivity and lethality of coronaviruses.
The enzyme furin is ubiquitous in the human body, found in multiple organ systems including lungs, heart, kidneys, brain and blood vessels.
The PRRA sequence found in COVID-19, does not exist in any of hundreds of close bat coronaviruses relatives from which COVID-19 could have evolved.
The 2018 DARPA research application proposed to artificially insert furin polybasic cleavage sites, like PRRA, into low-risk bat coronaviruses and then testing the ability of those laboratory-created viruses to infect human cells.
That application was ultimately rejected by DARPA because it involved dangerous “gain of function” experiments creating new human-infecting viruses, which also have the potential for dual use as bioweapons.
It is important to note that the section of the COVID-19 genetic code (CGG-CGG) that produces the “RR” segment of the PRRA sequence is extremely rare.
The two tandem CGG codons do not appear anywhere else in the COVID-19 genetic code, nor does it exist in that context in any close bat coronavirus relative of COVID-19.
Thus, CGG-CGG is a unique marker both as an indicator of its laboratory origin and its potential role as a designed feature of the disease process.
According to a 2020 scientific article, the COVID-19 furin polybasic cleavage site (PRRA) and its surrounding structures may be far more toxic than first realized.
The approximately 20 amino acids surrounding COVID-19’s furin polybasic cleavage site possess sequence and structural elements comparable to those of Staphylococcal enterotoxin B (SEB).
SEB acts as a “superantigen” and immune system activator stimulating the release large amounts of cytokines, often called “cytokine storm” and capable of producing multi-organ hyperinflammation similar to toxic shock syndrome.
The authors also state that COVID-19 mutations strengthen its “superantigen” character.
As a confirmation of those observations, the same authors demonstrated that monoclonal antibodies directed against Staphylococcal enterotoxin B “superantigen” inhibit the entry of the COVID-19 virus into cultured cells.
It may be no accident that China’s People’s Liberation Army’s Third Military Medical University has done extensive research on SEB and “superantigens,” because that center has been implicated in the creation of COVID-19 and is associated with the recent monoclonal antibody “cure” announced for COVID-19.
Caution, therefore, is warranted regarding mandating COVID-19 mRNA vaccines, which initiate the synthesis of spike protein inside the human body and may replicate the toxic structures introduced into COVID-19, potentially becoming a causative factor in organ inflammation.
A scientific abstract published on November 8, 2021 concludes that the mRNA vaccines:
dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.
Finally, it may be purely coincidental that Moderna, a biotechnology company that produces a COVID-19 mRNA vaccine, holds a patent (US 10,501,513 B2), filed on February 7, 2017, describing “protein cleavage” sites and including a complementary genetic sequence matching that for the furin polybasic cleavage site found in COVID-19.
Lawrence Sellin, Ph.D. is a retired U.S. Army Reserve colonel and a veteran of Afghanistan and Iraq. He had a civilian career in international business and medical research. His email address is firstname.lastname@example.org